MedinCell's Stock Jumps 3.24% and Crosses a Key Technical Threshold
The stock of the French pharmaceutical company broke through its technical resistance at €27.16 during the session on Wednesday, October 8, confirming a particularly marked bullish momentum. This technical breakout comes after several unsuccessful attempts by the stock to exceed this level, which had previously acted as a ceiling for the prices. Crossing this resistance zone now paves the way for new bullish targets for the stock, in a context of strong sustained demand.
MedinCell closed the session at €28.04, up 3.24% from the previous day, with a trading volume representing 0.5% of the capital. This performance is part of a sustained upward trend, with a cumulative gain of 18.01% over the last seven days and a surge of 73.09% over three months. The stock's valuation has more than doubled over twelve months with an increase of 82.55%, significantly outperforming the CAC 40's 6.39% over the same period. The Relative Strength Index (RSI) now reaches 96, an extreme level indicating a pronounced technical overbought condition. This measure, which generally oscillates between 0 and 100, suggests that the stock might experience a pause or a correction in the short term. Concurrently, the Chaikin Money Flow is established at 0.16, confirming the presence of net buying flows that support the current bullish trend.
Graphical Analysis and Market Behavior
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Graphically, the stock is now trading above all its significant moving averages, with a gap of 46.41% from its 50-day moving average (€19.15) and 71.41% above its 200-day moving average (€16.36). This technical configuration reflects a solid bullish momentum and confirms the strength of the underlying trend. The MACD shows a positive setup with a main line at 2.11 above its signal line (1.63), while the MACD histogram at 0.47 indicates an acceleration of the bullish momentum. The monthly volatility of the stock stands at 8.23%, a moderate level that contrasts with the magnitude of recent gains. With a beta of only 0.02, MedinCell shows almost no correlation with the movements of the CAC 40, which advanced 1.07% today. The Bollinger Bands, ranging between €17.50 and €27.49, now see the course moving above the upper limit, signaling a significant technical extension that may require a consolidation phase.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
